KPC(SH:600422) Xi Niu Cai Jing·2025-04-28 10:10Financial Performance - In 2024, the company achieved operating revenue of 8.401 billion yuan, a slight decrease of 0.34% year-on-year [2] - The net profit for 2024 was 648 million yuan, representing a year-on-year increase of 19.86% [2] - The non-recurring net profit reached 419 million yuan, up 25.09% compared to the previous year [2] - Basic earnings per share were 0.86 yuan, an increase of 21.13% from 0.71 yuan in 2023 [3] Key Financial Metrics - The weighted average return on equity was 9.52%, an increase of 0.97 percentage points from 8.55% in 2023 [3] - Operating cash flow net amount was 808 million yuan, reflecting a year-on-year growth of 7.12% [3] - Net assets decreased by 19.94% year-on-year to 5.253 billion yuan [3] Business Segment Analysis - Oral liquid revenue was 3.692 billion yuan, a year-on-year increase of 1.18%, with a gross margin decrease of 2.11 percentage points [4] - Injection revenue fell to 539 million yuan, down 49.09% year-on-year, with a gross margin decrease of 0.84 percentage points [4] - Revenue from the retail and wholesale of drugs and medical devices was 3.655 billion yuan, a decline of 3.72% year-on-year, with a gross margin decrease of 1.58 percentage points [4] Product Performance - The cardiovascular sector remained the main revenue contributor with 2.195 billion yuan, a year-on-year decline of 17.45% [4] - Revenue from the digestive system drugs was 548 million yuan, showing a growth of 2.46% [4] - Gynecological products generated 401 million yuan, an increase of 15.67% year-on-year [4] Research and Development - The company invested 143 million yuan in R&D, with 20 new patents granted [4] - The first-class innovative drug KPC000154 (for non-alcoholic fatty liver) entered clinical trials [4] - The second-class modified new drug KYAH02-2020-149 received approval for trials [4] - Progress in generic drugs included the consistency evaluation of chlorazepate injection and colchicine tablets [4] Dividend Distribution - The company plans to distribute a cash dividend of 3.0 yuan per 10 shares (including tax) [4]